13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595725
Total reported value
$2.0B
$2.0B
107 檔
27.3%
The Q4 2024 SEC filing reveals that Rock Springs Capital Management LP held a total portfolio value of $2.0B, covering 107 public equity positions.
Rock Springs Capital Management LP executed strategic sector rebalancing during Q4 2024, establishing 10 new positions while fully exiting 12 holdings and trimming 30 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.38% | -1.85% | -1.67% | |
| 2 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.29% | -0.75% | -20.00% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.25% | +0.43% | +1.76% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.74% | +0.02% | -23.27% | |
| 5 | 2655787D | Blueprint Medicines CORP | Stock-Other | 3.64% | — | +42.68% | |
| 6 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.39% | +0.44% | -40.19% | |
| 7 | TVTX | Travere Therapeutics Inc | Stock-Other | 3.30% | +3.45% | +6.17% | |
| 8 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.12% | -0.69% | +0.82% | |
| 9 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.79% | +0.08% | -12.05% | |
| 10 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.48% | +0.21% | -5.32% | |
| 11 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.32% | +0.14% | -6.89% | |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.30% | -0.46% | +2.48% | |
| 13 | PEN | Penumbra Inc | Stock-Healthcare | 2.17% | -0.55% | -9.43% | |
| 14 | WST | West Pharmaceutical Services | Stock-Healthcare | 2.10% | — | +0.60% | |
| 15 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.02% | +3.17% | +20.13% | |
| 16 | PHR | Phreesia Inc | Stock-Other | 1.95% | +0.05% | -10.62% | |
| 17 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.87% | -0.61% | -4.91% | |
| 18 | FRPT | Freshpet Inc | Stock-Consumer Staples | 1.85% | — | -26.65% | |
| 19 | ASND | Ascendis Pharma A/S | Stock-Other | 1.60% | -2.62% | EXIT | |
| 20 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.58% | +0.10% | -1.45% | |
| 21 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.56% | -0.81% | — | |
| 22 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.54% | -0.14% | EXIT | |
| 23 | INSM | Insmed Inc | Stock-Healthcare | 1.45% | -1.15% | -19.51% | |
| 24 | ✓ | Merus N V | Stock-Other | 1.43% | — | — | |
| 25 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.42% | — | — | |
| 26 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.36% | -0.25% | — | |
| 27 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.30% | -0.14% | -0.79% | |
| 28 | NUVL | Nuvalent Inc-a | Stock-Other | 1.28% | — | — | |
| 29 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 1.28% | — | +0.68% | |
| 30 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.18% | -0.22% | — | |
| 31 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.18% | +0.05% | +10.73% | |
| 32 | PODD | Insulet CORP | Stock-Healthcare | 1.14% | — | -14.74% | |
| 33 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.12% | -0.14% | +1.60% | |
| 34 | DXCM | Dexcom Inc | Stock-Healthcare | 1.05% | -0.19% | -32.63% | |
| 35 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.00% | — | +1.40% | |
| 36 | EXK | Exact Sciences CORP | Stock-Materials | 0.96% | — | -60.78% | |
| 37 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.93% | -0.02% | EXIT | |
| 38 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.92% | +0.13% | — | |
| 39 | AZTA | Azenta Inc | Stock-Other | 0.90% | -0.21% | -10.80% | |
| 40 | EVH | Evolent Health Inc - A | Stock-Other | 0.88% | +0.30% | -0.48% | |
| 41 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.88% | -0.10% | EXIT | |
| 42 | IMVT | Immunovant Inc | Stock-Other | 0.86% | — | -25.56% | |
| 43 | WRBY | Warby Parker Inc-class A | Stock-Other | 0.85% | — | -36.07% | |
| 44 | VERA | Vera Therapeutics Inc | Stock-Other | 0.79% | -0.29% | +27.22% | |
| 45 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.77% | — | -26.07% | |
| 46 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.75% | -0.15% | +117.23% | |
| 47 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.72% | -0.28% | +1.35% | |
| 48 | LFST | Lifestance Health Group Inc | Stock-Other | 0.72% | — | -17.77% | |
| 49 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.63% | +0.01% | +0.63% | |
| 50 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.62% | -0.25% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 2655787D | Blueprint Medicines CORP | +1.3% | +42.68% | Add |
| 2 | MDGL | Madrigal Pharmaceuticals Inc | +1.3% | +0.82% | Add |
| 3 | ARGX | Argenx Se - Adr | +1.3% | -1.67% | Trim |
| 4 | SRRK | Scholar Rock Holding CORP | +1.2% | NEW | New buy |
| 5 | TVTX | Travere Therapeutics Inc | +1.2% | +6.17% | Add |
| 6 | THC | Tenet Healthcare CORP | +0.6% | NEW | New buy |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | +0.6% | +117.23% | Add |
| 8 | RVMD | Revolution Medicines Inc | +0.5% | +20.13% | Add |
| 9 | AM6 | Amicus Therapeutics Inc | +0.5% | +107.91% | Add |
| 10 | ACRS | Aclaris Therapeutics Inc | +0.5% | +125.32% | Add |
| 11 | PEN | Penumbra Inc | +0.5% | -9.43% | Trim |
| 12 | WST | West Pharmaceutical Services | +0.5% | +0.60% | Add |
| 13 | JANX | Janux Therapeutics Inc | +0.4% | NEW | New buy |
| 14 | IRTC | Irhythm Holdings Inc | +0.4% | — | Unchanged |
| 15 | RYTM | Rhythm Pharmaceuticals Inc | +0.4% | -5.32% | Trim |
| 16 | BSX | Boston Scientific CORP | +0.3% | — | Unchanged |
| 17 | MIRM | Mirum Pharmaceuticals Inc | +0.3% | -6.89% | Trim |
| 18 | EW | Edwards Lifesciences CORP | +0.3% | -5.53% | Trim |
| 19 | ARDX | Ardelyx Inc | +0.3% | NEW | New buy |
| 20 | ZLAB | Zai Lab Ltd-adr | +0.3% | -0.79% | Trim |
| 21 | PHR | Phreesia Inc | +0.3% | -10.62% | Trim |
| 22 | SWTXUSD | Springworks Therapeutics Inc | +0.2% | +64.57% | Add |
| 23 | VERA | Vera Therapeutics Inc | +0.2% | +27.22% | Add |
| 24 | TARS | Tarsus Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 25 | NBIX | Neurocrine Biosciences Inc | +0.2% | -23.27% | Trim |
| 26 | SLNOEUR | Soleno Therapeutics Inc | +0.2% | NEW | New buy |
| 27 | XENE | Xenon Pharmaceuticals Inc | +0.2% | -4.91% | Trim |
| 28 | SRPT | Sarepta Therapeutics Inc | +0.2% | — | Unchanged |
| 29 | LLY | Eli Lilly & Co | +0.2% | +1.76% | Add |
| 30 | ETNBGBP | 89bio Inc | +0.2% | NEW | New buy |
| 31 | PODD | Insulet CORP | +0.1% | -14.74% | Trim |
| 32 | AKRO | Akero Therapeutics Inc | +0.1% | +1.40% | Add |
| 33 | PHVS | Pharvaris N.V. | +0.1% | +2.40% | Add |
| 34 | JSPR | Jasper Therapeutics Inc | +0.1% | +0.87% | Add |
| 35 | WRBY | Warby Parker Inc-class A | +0.1% | -36.07% | Trim |
| 36 | XNCR | Xencor Inc | +0.1% | — | Unchanged |
| 37 | CRNX | Crinetics Pharmaceuticals In | +0.1% | +1.62% | Add |
| 38 | NGNE | Neurogene Inc | +0.1% | NEW | New buy |
| 39 | ATEC | Alphatec Holdings Inc | +0.1% | NEW | New buy |
| 40 | SGMT | Sagimet Biosciences Inc-a | +0.1% | — | Unchanged |
| 41 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | +2.48% | Add |
| 42 | AZTA | Azenta Inc | +0.1% | -10.80% | Trim |
| 43 | PLRX | Pliant Therapeutics Inc | +0.1% | +5.14% | Add |
| 44 | BEAM | Beam Therapeutics Inc | 0% | +0.92% | Add |
| 45 | INSP | Inspire Medical Systems Inc | 0% | — | Unchanged |
| 46 | LENZ | Lenz Therapeutics Inc | 0% | NEW | New buy |
| 47 | NMRA | Neumora Therapeutics Inc | 0% | +15.34% | Add |
| 48 | ✓ | Xilio Therapeutics Inc | 0% | — | Unchanged |
| 49 | CYPH | Cypherpunk Technologies Inc | 0% | — | Unchanged |
| 50 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, Rock Springs Capital Management LP reported a total U.S. public equity portfolio value of $2.0B across 107 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, ISRG, LLY) accounted for 27.3% of total reported equity market value during Q4 2024.
Top New Position Initiated
SRRK
市值: $31.0M
Top Position Liquidated / Trimmed
HUM
前期市值: $46.9M
During Q4 2024, Rock Springs Capital Management LP's top holdings by market value included ARGX (5.4%)、ISRG (4.3%)、LLY (4.3%). The largest single position, ARGX, represented 5.4% of total portfolio value.
In Q4 2024, Rock Springs Capital Management LP made 90 total portfolio adjustments, initiating 10 new buys, adding to 38 positions, trimming 30 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.